154 related articles for article (PubMed ID: 12892072)
1. The Tg.AC mouse model passes test by failing to respond.
Cannon RE
Toxicol Sci; 2003 Aug; 74(2):233-4. PubMed ID: 12892072
[No Abstract] [Full Text] [Related]
2. The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model.
Tennant RW; Stasiewicz S; Eastin WC; Mennear JH; Spalding JW
Toxicol Pathol; 2001; 29 Suppl():51-9. PubMed ID: 11695562
[TBL] [Abstract][Full Text] [Related]
3. Tg.AC genetically altered mouse: assay working group overview of available data.
Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questions.
Sistare FD; Thompson KL; Honchel R; DeGeorge J
Int J Toxicol; 2002; 21(1):65-79. PubMed ID: 11936901
[TBL] [Abstract][Full Text] [Related]
5. Statistical analysis of skin tumor data from Tg.AC mouse bioassays.
Dunson DB; Haseman JK; van Birgelen AP; Stasiewicz S; Tennant RW
Toxicol Sci; 2000 Jun; 55(2):293-302. PubMed ID: 10828260
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components.
Thompson KL; Rosenzweig BA; Weaver JL; Zhang J; Lin KK; Sistare FD
Toxicol Sci; 2003 Aug; 74(2):271-8. PubMed ID: 12773758
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness.
Thompson KL; Rosenzweig BA; Sistare FD
Toxicol Pathol; 1998; 26(4):548-55. PubMed ID: 9715514
[TBL] [Abstract][Full Text] [Related]
8. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype.
Weaver JL; Contrera JF; Rosenzweig BA; Thompson KL; Faustino PJ; Strong JM; Ellison CD; Anderson LW; Prasanna HR; Long-Bradley PE; Lin KK; Zhang J; Sistare FD
Toxicol Pathol; 1998; 26(4):532-40. PubMed ID: 9715512
[TBL] [Abstract][Full Text] [Related]
10. Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin tumors in Tg.AC mice.
Spalding JW; French JE; Tice RR; Furedi-Machacek M; Haseman JK; Tennant RW
Toxicol Sci; 1999 Jun; 49(2):241-54. PubMed ID: 10416269
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of SEPA 0009-induced tumorigenesis in v-rasHa transgenic Tg.AC mice.
Fuhrman J; Shafer L; Repertinger S; Chan T; Hansen LA
Toxicol Pathol; 2005; 33(6):623-30. PubMed ID: 16176921
[TBL] [Abstract][Full Text] [Related]
12. Oral and dermal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces cutaneous papillomas and squamous cell carcinomas in female hemizygous Tg.AC transgenic mice.
Wyde ME; Braen AP; Hejtmancik M; Johnson JD; Toft JD; Blake JC; Cooper SD; Mahler J; Vallant M; Bucher JR; Walker NJ
Toxicol Sci; 2004 Nov; 82(1):34-45. PubMed ID: 15282402
[TBL] [Abstract][Full Text] [Related]
13. Genetically altered mouse models for identifying carcinogens.
Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
[No Abstract] [Full Text] [Related]
14. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
15. Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays.
Spalding JW; French JE; Stasiewicz S; Furedi-Machacek M; Conner F; Tice RR; Tennant RW
Toxicol Sci; 2000 Feb; 53(2):213-23. PubMed ID: 10696769
[TBL] [Abstract][Full Text] [Related]
16. Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice.
Urano K; Suzuki S; Machida K; Eguchi N; Sawa N; Kikuchi K; Hattori Y; Usui T
J Toxicol Sci; 2007 Oct; 32(4):367-75. PubMed ID: 17965551
[TBL] [Abstract][Full Text] [Related]
17. Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro.
Thompson KL; Sistare FD
Toxicol Sci; 2003 Aug; 74(2):260-70. PubMed ID: 12730611
[TBL] [Abstract][Full Text] [Related]
18. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
Tamaoki N
Toxicol Pathol; 2001; 29 Suppl():81-9. PubMed ID: 11695564
[TBL] [Abstract][Full Text] [Related]
19. A perspective on current and future uses of alternative models for carcinogenicity testing.
Goodman JI
Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
[TBL] [Abstract][Full Text] [Related]
20. A transgenic mouse model (TG.AC) for skin carcinogenesis: inducible transgene expression as a second critical event.
Hansen LA; Spalding JW; French JE; Tennant RW
Prog Clin Biol Res; 1995; 391():223-35. PubMed ID: 8532720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
